Ever because the discovery that monoclonal antibodies could possibly be generated, scientists have targeted the creation of "fully" human antibodies to prevent a number of the unwanted effects of humanised or chimeric antibodies. Two profitable approaches have already been identified: transgenic mice and phage show.
Transgenic mice technologies is by far probably the most effective method to generating "fully" human monoclonal antibody therapeutics: 7 of the 9 "fully" human monoclonal antibody therapeutics on the market place were derived in this manner.
Transgenic mice have been exploited by many industrial organisations:
Medarex - who marketed their UltiMab platform. Medarex had been acquired in July 2009 by Bristol Myers Squibb
Abgenix - who marketed their Xenomouse technology. Abgenix were acquired in April 2006 by Amgen.
Regeneron's VelocImmune technology.
Kymab - who industry their Kymouse technologies.
Related tags : antibody company , membrane proteins